Syntara Pauses SNT-9465 Trial Recruitment Over Skin Irritation
SNT: $0.016 -15.79% · MC: $28M
Syntara has paused recruitment in its Phase 1b SNT-9465 scar study after reports of mild to moderate skin irritation among some participants. The company will review unblinded data before deciding whether to resume recruitment or discontinue the study, with the review expected to finish this quarter.

Comments